Molecular Mechanisms Related to Hormone Inhibition Resistance in Prostate Cancer

被引：40

作者：

Mollica, Veronica ^{[1
]}

Di Nunno, Vincenzo ^{[1
]}

Cimadamore, Alessia ^{[2
]}

Lopez-Beltran, Antonio ^{[3
]}

Cheng, Liang ^{[4
]}

Santoni, Matteo ^{[5
]}

Scarpelli, Marina ^{[2
]}

Montironi, Rodolfo ^{[2
]}

Massari, Francesco ^{[1
]}

机构：

[1] St Orsola Marcello Malpighi Hosp, Div Oncol, I-40138 Bologna, Italy

[2] Polytech Univ Marche Reg, Sect Pathol Anat, Sch Med, United Hosp, I-60126 Ancona, Italy

[3] Cordoba Univ, Sch Med, Dept Surg, Cordoba 14071, Spain

[4] Indiana Univ Sch Med, Dept Pathol & Lab Med, Indianapolis, IN 46202 USA

[5] Macerata Hosp, Oncol Unit, I-62012 Macerata, Italy

来源：

CELLS | 2019年 / 8卷 / 01期

关键词：

hormone inhibition resistance; prostate cancer (PCa); castration-resistance PCa; AR splice variants; epigenetic mechanisms; ANDROGEN-DEPRIVATION THERAPY; RADICAL PROSTATECTOMY; INCREASED SURVIVAL; DNA METHYLATION; SPLICE VARIANTS; RECEPTOR; ENZALUTAMIDE; ABIRATERONE; PTEN; PROGRESSION;

D O I：

10.3390/cells8010043

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Management of metastatic or advanced prostate cancer has acquired several therapeutic approaches that have drastically changed the course of the disease. In particular due to the high sensitivity of prostate cancer cells to hormone depletion, several agents able to inhibit hormone production or binding to nuclear receptor have been evaluated and adopted in clinical practice. However, despite several hormonal treatments being available nowadays for the management of advanced or metastatic prostate cancer, the natural history of the disease leads inexorably to the development of resistance to hormone inhibition. Findings regarding the mechanisms that drive this process are of particular and increasing interest as these are potentially related to the identification of new targetable pathways and to the development of new drugs able to improve our patients' clinical outcomes.

引用

页数：15

共 79 条

[1] Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer [J].

Asangani, Irfan A. ;

Dommeti, Vijaya L. ;

Wang, Xiaoju ;

Malik, Rohit ;

Cieslik, Marcin ;

Yang, Rendong ;

Escara-Wilke, June ;

Wilder-Romans, Kari ;

Dhanireddy, Sudheer ;

Engelke, Carl ;

Iyer, Mathew K. ;

Jing, Xiaojun ;

Wu, Yi-Mi ;

Cao, Xuhong ;

Qin, Zhaohui S. ;

Wang, Shaomeng ;

Feng, Felix Y. ;

Chinnaiyan, Arul M. .

NATURE, 2014, 510 (7504) :278-+

[2] Emerging cell cycle inhibitors for treating metastatic castration-resistant prostate cancer [J].

Batra, Anupam ;

Winquist, Eric .

EXPERT OPINION ON EMERGING DRUGS, 2018, 23 (04) :271-282

[3]

Beer TM, 2014, NEW ENGL J MED, V371, P424, DOI 10.1056/NEJMoa1405095

[4] Covalent modifications of histones during development and disease pathogenesis [J].

Bhaumik, Sukesh R. ;

Smith, Edwin ;

Shilatifard, Ali .

NATURE STRUCTURAL & MOLECULAR BIOLOGY, 2007, 14 (11) :1008-1016

[5] Radical Prostatectomy or Watchful Waiting in Early Prostate Cancer [J].

Bill-Axelson, Anna ;

Holmberg, Lars ;

Garmo, Hans ;

Rider, Jennifer R. ;

Taari, Kimmo ;

Busch, Christer ;

Nordling, Stig ;

Haggman, Michael ;

Andersson, Swen-Olof ;

Spangberg, Anders ;

Andren, Ove ;

Palmgren, Juni ;

Steineck, Gunnar ;

Adami, Hans-Olov ;

Johansson, Jan-Erik .

NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (10) :932-942

[6] The role of epithelial plasticity in prostate cancer dissemination and treatment resistance [J].

Bitting, Rhonda L. ;

Schaeffer, Daneen ;

Somarelli, Jason A. ;

Garcia-Blanco, Mariano A. ;

Armstrong, Andrew J. .

CANCER AND METASTASIS REVIEWS, 2014, 33 (2-3) :441-468

[7] Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer [J].

Carver, Brett S. ;

Chapinski, Caren ;

Wongvipat, John ;

Hieronymus, Haley ;

Chen, Yu ;

Chandarlapaty, Sarat ;

Arora, Vivek K. ;

Le, Carl ;

Koutcher, Jason ;

Scher, Howard ;

Scardino, Peter T. ;

Rosen, Neal ;

Sawyers, Charles L. .

CANCER CELL, 2011, 19 (05) :575-586

[8] Src promotes castration-recurrent prostate cancer through androgen receptor-dependent canonical and non-canonical transcriptional signatures [J].

Chattopadhyay, Indranil ;

Wang, Jianmin ;

Qin, Maochun ;

Gao, Lingqiu ;

Holtz, Renae ;

Vessella, Robert L. ;

Leach, Robert W. ;

Gelman, Irwin H. .

ONCOTARGET, 2017, 8 (06) :10324-10347

[9] Implications of PI3K/AKT inhibition on REST protein stability and neuroendocrine phenotype acquisition in prostate cancer cells [J].

Chen, Ruiqui ;

Li, Yinan ;

Buttyan, Ralph ;

Dong, Xuesen .

ONCOTARGET, 2017, 8 (49) :84863-84876

[10] Prostate cancer heterogeneity: Discovering novel molecular targets for therapy [J].

Ciccarese, Chiara ;

Massari, Francesco ;

Iacovelli, Roberto ;

Fiorentino, Michelangelo ;

Montironi, Rodolfo ;

Di Nunno, Vincenzo ;

Giunchi, Francesca ;

Brunelli, Matteo ;

Tortora, Giampaolo .

CANCER TREATMENT REVIEWS, 2017, 54 :68-73

← 1 2 3 4 5 6 7 8 →